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Abstract
Background—To explore the distribution of etiologies and risk factors of upper gastrointestinal
hemorrhage (UGH) in the context of new pharmacologic therapies that may alter risk of UGH.
Methods—Retrospective study was performed on eligible UGH inpatients at two academic
medical centers, between July 1, 2001-June 30, 2003. Administrative data and chart review were
used to identify demographics, UGH risk factors and etiologies. Bivariate and multivariate
analyses were performed to describe distributions and associations of risk factors and etiologies.
Results—UGH was identified in 227 subjects, with erosive disease (n=99, 44%), peptic ulcer
disease (n=75, 33%) and variceal bleeds (n=39, 17%) accounting for the majority of bleeds.
Known risk factors for UGH occurred in 70% (n=156) of subjects (prior UGH 43% (n=90),
NSAID use 23% (n=52), ASA use 25% (n=57), NSAID + ASA use 6.6%(n=15)), while 19%
(n=42) were using a proton-pump inhibitor and 5% (n=11) a cyclooxygenase-2 inhibitor. Subjects
at site 1 were more likely to have erosive disease (OR 7.1, P<0.001) and less likely to have
variceal bleeding (OR 0.12, P=0.009) in multivariate analyses. Preventive therapy did not differ
between sites.
Conclusions—Unlike older studies, peptic ulcer disease was not the most common etiology,
suggesting that advances in H pylori eradication may affect the epidemiology of UGH. Despite
advances in therapeutics of acid-related disease, erosive disease accounted for the majority of
UGH. Most subjects had risk factors for UGH and most were not receiving protective therapy.
Large between site differences in the distribution of etiologies existed.
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Upper gastrointestinal hemorrhage (UGH) is a common cause of acute admission for
hospitalization.1-3 However, recent advances in our understanding of erosive disease and
peptic ulcer disease (PUD), two of the most common etiologies of UGH, have led to
effective strategies to reduce the risk of UGH. Successful implementation of these strategies,
such as treatment of Helicobacter pylori and the use of proton pump inhibitors (PPIs) and
selective cyclooxygenase-2 inhibitors (COX-2s) in place of traditional non-selective
NSAIDs, may be able to significantly reduce rates of UGH caused by erosive disease and
PUD.4-7
Prior to these preventive treatments, PUD and erosive disease both acid related disorders,
were the most common causes of UGH requiring admission to the hospital, accounting for
62% and 14% of all UGHs respectively.2 Given the widespread treatment of H. pylori and
use of PPIs and COX-2s, we might expect that the distribution of etiologies of UGH may
have changed. However, there are limited data on the distribution of etiologies of UGH in
the era of effective preventive therapy.8 If the distribution of etiologies causing patients to
present with UGH has fundamentally changed with these new treatments, established
strategies of managing acute UGH may need to be re-evaluated. Given that well established
guidelines exist and that many hospitals use a protocol-driven management strategy to
decide on the need for admission and/or intensive care unit (ICU) admission, changes in the
distribution of etiologies since the widespread use of these new pharmacologic approaches
may affect the appropriateness of these protocols.9,10 For example, if the eradication of H
pylori has dramatically reduced the proportion of UGH caused by PUD then risk
stratification studies developed when PUD was far more common may need to be re-visited.
This would be particularly important if bleeding from PUD was of significantly different
severity than bleeding from other causes.
While patients with H. pylori related UGH from PUD should be treated for H. pylori
eradication, several important questions remain surrounding the use of newer therapeutics
that may mitigate the risk of UGH in some patients. It is unclear what proportion of patients
admitted with UGH in this new era developed bleeding despite using preventive therapy.
These treatment failures are known to occur, but it is not well known how much of the
burden of UGH today is due to this breakthrough bleeding. 5,6,11,12 Contrastingly, there are
also patients who are admitted with UGH who are not on preventive treatment. Current
guidelines suggest that high-risk patients requiring NSAIDs be given COX-2s or traditional
NSAIDs with a PPI.13-15 However, there is significant disagreement between these national
guidelines about what constitutes a high-risk profile. 13-15 For example, some guidelines
recommend that elderly patients requiring NSAIDs should be on a PPI while others do not
make that recommendation. Similarly, while prior UGH is a well recognized risk factor for
future bleeding risk even without NSAIDs, current guidelines do not provide guidance
towards the use of preventive therapy in these patients. If there are few patients who present
with UGH related to acid disease that are not on a preventive therapy, then these
unanswered questions or conflicts within current guidelines become less important.
However, if a large portion of UGH is due to acid related disease in patients not on
preventive therapy, then these unanswered questions may become important for future
research.
In contrast to previous studies, the current study examines the distribution of etiologies of
UGH in the era of widespread use of effective preventive therapy for erosive disease and
PUD in two US academic medical centers. Prior studies were done before the advent of new
therapeutics and did not compare different sites which may be important. 16,17
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Consecutive patients admitted with UGH were identified at two academic medical centers as
part of a larger observational study examining the impact of hospitalist physicians on the
care of acute medical patients.18 The sample was selected from the 12,091 consecutive
general medical patients admitted from July 2001-June 2003 with UGH identified by
International Classification of Diseases, Ninth revision, Clinical Modification (ICD-9 CM)
codes from administrative data and confirmed by chart abstraction. ICD-9 CM codes for
UGH included: esophageal varices with hemorrhage (456.0, 456.20), Mallory-Weiss
syndrome (530.7), gastric ulcer with hemorrhage (531.00-531.61), duodenal ulcer with
hemorrhage (532.00-532.61), peptic ulcer, site unspecified, with hemorrhage
(533.00-533.61), gastrojejunal ulcer with hemorrhage (534.00-534.61), gastritis with
hemorrhage (535.61), angiodysplasia of stomach/duodenum with hemorrhage (537.83), and
hematemesis (578.0, 578.9).19 Finally, the admission diagnoses for all patients in the larger
cohort were reviewed and any with gastrointestinal hemorrhage were screened for possible
inclusion to account for any missed ICD-9 codes. Subjects were then included in this
analysis if they had observed hematemesis, NG tube aspirate with gross or hemoccult blood,
or history of hematemesis, bloody diarrhea, or melena upon chart review.
Data
The inpatient medical records were abstracted by trained researchers. Etiologies of UGH
were assessed by esophagogastroduodenoscopy (EGD) report which listed findings and
etiologies as assessed by the endoscopist. Multiple etiologies were allowed if more than one
source of bleeding was identified. Prior medical history and pre-admission medication use
were obtained from three sources: 1. The emergency department medical record, 2. Nursing
admission documentation, and 3. The admission history and physical documentation. Risk
factors and pre-admission medication use were considered present if documented in any of
the three sources. Relevant past medical history included known risk factors for UGH
including: end-stage renal disease, alcohol abuse, prior history of UGH, and steroid use.
Prior H. pylori status/testing could not reliably be obtained from these data sources. Pre-
admission medication use of interest included aspirin, NSAIDS, anticoagulants, anti-platelet
agents, as well as PPIs and COX-2s. Demographics including age, race, and gender were
obtained from administrative databases.
We defined subjects as at-risk if they had any of the following risk-factors: prior UGH (at
any time), use of an NSAID (traditional or selective COX-2), or use of an aspirin prior to
admission. Patients taking COX-2s were included for two reasons. First, while COX-2
inhibitors are associated with a lower risk of UGH than traditional NSAIDs, it is likely that
they still lead to an increased risk of UGH compared to placebo. Secondly, if a patient
required NSAIDs of some type (traditional or selective), pre-admission use of a COX-2
rather than a traditional NSAID may reflect the intention of decreasing the risk of UGH
compared to using traditional NSAIDs. In order to use the most conservative estimate of
potential missed opportunities for prevention, pre-admission use of a PPI or COX-2 was
considered preventive therapy. All pre-admission medication use was obtained from chart
review. Therefore duration of and purpose for medication use were not available.
Development of the abstraction tool was performed by the authors. Testing of the tool was
performed on a learning set of 20 charts at each center. All additional abstractors were
trained with a learning set of at least 20 charts to assure uniform abstraction techniques.
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For each risk factor and etiology, we calculated the proportion of patients with the risk
factor or etiology both overall and by site. Differences in risk factors between sites were
assessed using chi-squared tests of association. Differences in etiologies between sites were
assessed using unadjusted odds ratios as well as odds ratios from logistic regression models
controlling for age, gender and race (black versus not black). Center 1 was the urban center
and center 2 was the rural site.
This study was approved by the Institutional Review Board at the University of Iowa Carver
College of Medicine and the University of Chicago.
Results
From the entire cohort of 12,091 admitted to the two inpatient medical services, 227 (1.9%)
patients were identified as having UGH; 138 (61%) were from center 1 where 87% of
patients were black and 89 (39%) were from center 2 where 89% of patients were white.
Overall, the mean age was 59 years, 45% were female, and 41% were white. (Table 1)
The most common etiologies of UGH were erosive disease (44%), PUD (33%), and varices
(17%) in the overall population. These same three etiologies were also the most common in
both of the medical centers, although, there were significant differences in the rates of
etiologies between the two centers. Erosive disease was more common among subjects from
center 1 (59%) than from center 2 (19%) (P<0.001), while variceal bleeding was more
common among subjects from center 2 (34%) than from center 1 (6.5%) (P=0.009). (Table
2)
In multivariate logistic regression analyses, only age and site remained independent
predictors of etiologies. Advancing age was associated with a higher risk of arteriovenous
malformations (AVMs) with the odds of AVMs increasing 6% for every additional year of
life (P=0.007). Site was associated with both erosive disease and variceal bleeding. Patients
from center 1 were significantly more likely to have UGH caused by erosive disease with an
odds ratio of 7.10 (P<0.001) compared to subjects from center 2. However, subjects from
center 1 had a significantly lower odds ratio (OR= 0.12) than those subjects at center 2
(P=0.009) of having UGH caused by a variceal bleed. (Table 2)
Risk factors for UGH were common among these patients, including use of aspirin (25.1%),
NSAIDs (22.9%), COX-2s (4.9%), or prior history of UGH (43%). Additionally, 6.6% of
patients were taking both an NSAID and aspirin. Differences between the two sites were
seen only in aspirin use, with 34.8% of patients in the center 1 population using aspirin
compared to 10.1% in center 2, (P<0.001). (Table 3)
Among the overall population, 68.7% of patients had identifiable risk factors (Prior history
of UGH or pre-admission use of aspirin, NSAIDs, or COX-2s). 18.5% of all subjects were
on PPIs and 4.9% were taking COX-2s while 21.1% of at risk subjects were on PPIs and
6.5% of these subjects were on a COX-2.
Finally, we examined the effects of variations in pre-admission medication use between the
sites on the etiologies of UGH. None of the site-based differences in etiologies could be
explained by differences in pre-admission medication patterns.
Discussion
Despite the emergence of effective therapies for lowering the risk of erosive disease and
PUD, these remain the most common etiologies of UGH in our cohort of patients. In a
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dramatic change from historically reported patterns, erosive disease was more common than
PUD. In prior studies, PUD accounted for almost 2/3 of all UGH. 2 While some of the newer
therapeutics such as PPIs and COX-2s, reduce the risk for acid related bleeding of all types,
H. pylori eradication is effective primarily for PUD. Therefore, it may be that widespread
testing and treatment of H. pylori have dramatically decreased rates of PUD. Unfortunately,
this study does not allow us to directly evaluate the effect of H. pylori treatment on the
changing epidemiology of UGH as that would require a population based study.
While decreasing rates of PUD could explain a portion of the change in the distribution of
etiologies, increasing rates of erosive disease could also be playing a role. Prior studies have
suggested that African Americans and the elderly are more susceptible to erosive disease,
particularly in the setting of NSAIDs and/or aspirin and less susceptible to
cirrhosis. 13,16,17, 20-23 Our finding of a higher rate of erosive disease and lower rates of
cirrhosis in center 1 with a higher proportion of African Americans and greater aspirin use is
consistent with these prior findings. However, in multivariate analyses, neither race nor pre-
admission medication use patterns explained the differences in etiologies seen. This suggests
that some other factors must play a role in the differences between the two centers studied.
These results emphasize the importance of local site characteristics in the interpretation and
implementation of national guidelines and recommendations. This finding may be
particularly important in diseases and clinical presentations that rely on protocol driven
pathways, such as UGH. Current recommendations on implementing clinical pathways
derived from national guidelines emphasize the fact that national development and local
implementation optimization is probably the best approach for effective pathway
utilization.24
It is important to understand why erosive disease and PUD, for which we now have effective
pharmacologic therapies, continue to account for such a large percentage of the burden of
UGH. In this study, we found that a majority of subjects were known to have significant risk
factors for UGH (aspirin use, NSAID use, COX-2s, or prior UGH) and only 31% of the
subjects could not have been identified as at-risk prior to admission. PPIs or COX-2s should
neither be used universally as preventive therapy nor are they completely effective at
preventing UGH in at-risk patients. In this study, 2/3 of patients with risk factors were not
on preventive therapy, but almost 1/3 of patients with risk factors had bleeding despite being
on preventive therapy. A better understanding of why these treatment failures (bleeding
despite preventive therapy) occur may be helpful in our future ability to prevent UGH. This
study was not designed to determine if the 2/3 of patients not taking preventive therapy were
being treated consistent with established guidelines. However, current guidelines have
significant variation in recommendations about which patients are at high enough risk to
warrant preventive therapy.13-15 and there is no consensus about which patients are at high
enough risk to warrant preventive therapy. Our data suggest that additional studies will be
required to determine the optimal recommendations for preventive therapy among at-risk
patients.
There are several limitations to this study. First, it only included two academic institutions.
However, these institutions represented very different patient populations. Secondly, the
study design is not a population-based study. This limitation prevents us from addressing
questions such as the effectiveness or cost-effectiveness of interventions to prevent
admission for UGH. Although we analyzed pre-admission PPI or COX-2 use in at-risk
patients as preventive therapy, we are unable to determine the actual intent of the physician
in prescribing these drugs. Finally, although the mechanisms by which PPIs and COX-2
affect the risk of UGH are fundamentally different and should not be considered equivalent
choices, we chose to analyze either option as representing a preventive strategy in order to
provide the most conservative estimate possible of preventive therapy utilization rates.
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However, our assumptions would generally overestimate the use of preventive therapy (as
opposed to PPI use for symptom control) as we assumed all potentially preventive therapy
was intended as such.
This study highlights several unanswered questions that may be important in the
management of UGH. First, identifying factors that affect local patters of UGH may better
inform local implementation of nationally developed guidelines. Second, a more complete
understanding of the impact positive and negative risk factors for UGH have on specific
patient populations may allow for a more consistent targeted approach to using preventive
therapy in at risk patients.
Finally, and perhaps most importantly, is to determine if the change in distribution of
etiologies is in fact related to a decline in bleeding related to PUD. In addition to this being a
marker of the success of the H. pylori story, it may have important implications on our
understanding of the acute management of UGH. If PUD is of a different severity than other
common causes of UGH, such as erosive disease, current risk stratification prediction
models may need to be re-validated. For example, if UGH secondary to PUD results in
greater morbidity and mortality than UGH secondary to ED, our current models identifying
who requires ICU admission, urgent endoscopy, and other therapeutic interventions may
result in over utilization of these resource intensive interventions. However if larger studies
do not confirm this decline in PUD it suggests the need for additional studies to identify why
PUD remains so prevalent despite the major advances in treatment and prevention of PUD
through H.pylori identification and eradication.
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Table 1
Baseline Characteristics of 227 Consecutive Upper Gastrointestinal Hemorrhage (UGH) Patients Admitted to
2 Academic Medical Centers
Characteristic Total (n=227) Center 1 (n=138) Center 2 (n=89) P-value Center 1 vs. 2
Mean Age 58.6 59.5 57.1 0.317
% Female 44.5% 48.6% 38.2% 0.126
% White 41.2% 10.2% 88.8% <0.001
% African American 54.0% 86.9% 3.4%
% Other 4.9% 2.9% 7.9%
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Table 3
Prevalence of Positive and Negative Risk Factors for UGH
Risk Factor All Center 1 Center 2 P value
Previous UGH 42.7% 41.3% 45.2% 0.586
NSAID Use 22.9% 21.7% 24.7% 0.602
ASA Use 25.1% 34.8% 10.1% <0.001
NSAID + ASA 6.6% 6.5% 6.7% 0.948
COX- 2 Use 4.9% 6.5% 2.3% 0.143
PPI Use 18.5% 18.1% 19.1% 0.852
NSAID=non-steroidal anti-inflammatory drug, ASA=aspirin, COX=cyclooxygenase, PPI=proton-pump inhibitor
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